Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 0.98 is in line with its estimated 1-year average of 1.04, around the middle of its estimated 1-year range (0.91–1.14).
As of 2026-10-06T17:57:13.408Z.
Calculation as of: 2026-10-06T17:57:13.408Z.
Quote observation: 2026-10-06T17:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 757805bafeebc6dd018a704dcae2ac70006cc574d7bdbc7e38b059e75a8ad8a2
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
0.98
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.23
median of 573 covered companies
CURRENT VS SECTOR MEDIAN
-76.83%
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.02B
PS Ratio
0.98
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
PS Ratio
32.12
TTM Avg
417.15
3Y Avg
424.50
5Y Avg
312.33
Market Cap
$1.03B
PS Ratio
0.63
TTM Avg
0.65
3Y Avg
1.07
5Y Avg
1.84
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.02B | 0.98 | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 32.12 | 417.15 | 424.50 | 312.33 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | 45.53 | 45.53 | 45.53 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 0.63 | 0.65 | 1.07 | 1.84 |
| Immatics N.V. (IMTX)vs › | $1.04B | 21.33 | 20.87 | 13.31 | 11.88 |
| Vor Biopharma Inc. (VOR)vs › | $999.19M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 2.91 | 2.52 | 2.44 | 4.32 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $990.42M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.42 | 0.48 | 0.66 | 1.86 |
| MeiraGTx Holdings plc (MGTX)vs › | $984.44M | 2.48 | 15.04 | 25.67 | 23.89 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $258,944,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $267,734,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $252,537,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $264,162,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $1,043,377,000 |
Current P/S: $1,018,455,791 market capitalization ÷ $1,043,377,000 TTM revenue = 0.98x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:55:08.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 0.98, P/S is below its estimated 1-year median — higher than 28% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
0.91
median
1.06
estimated 1-year high
1.14
P/S Ratio
0.98
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 0.99 |
| 2026-10-02 | 0.95 |
| 2026-10-01 | 0.93 |
| 2026-09-30 | 0.94 |
| 2026-09-29 | 0.94 |
| 2026-09-28 | 0.93 |
| 2026-09-25 | 0.94 |
| 2026-09-24 | 0.91 |
| 2026-09-23 | 0.93 |
| 2026-09-22 | 0.97 |
| 2026-09-21 | 0.98 |
| 2026-09-18 | 1.02 |
| 2026-09-17 | 1.06 |
| 2026-09-16 | 1.07 |
| 2026-09-15 | 1.08 |
| 2026-09-14 | 1.05 |
| 2026-09-11 | 1.06 |
| 2026-09-10 | 1.03 |
| 2026-09-09 | 1.04 |
| 2026-09-08 | 1.06 |
| 2026-09-04 | 1.12 |
| 2026-09-03 | 1.10 |
| 2026-09-02 | 1.08 |
| 2026-09-01 | 1.07 |
| 2026-08-31 | 1.07 |
| 2026-08-28 | 1.06 |
| 2026-08-27 | 1.08 |
| 2026-08-26 | 1.10 |
| 2026-08-25 | 1.11 |
| 2026-08-24 | 1.09 |
| 2026-08-21 | 1.14 |
| 2026-08-20 | 1.07 |
| 2026-08-19 | 1.09 |
| 2026-08-18 | 1.10 |
| 2026-08-17 | 1.09 |
| 2026-08-14 | 1.11 |